Qyuns Therapeutics Co Ltd
02509
Company Profile
Business description
Qyuns Therapeutics Co Ltd is a a clinical-stage biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline. It has built a pipeline that covers the four disease areas in the field, including skin, rheumatic, respiratory and digestive diseases Key revenue is generated from PRC.
Contact
No. 907 Yaocheng Avenue
Room 1310, Building 1
Taizhou
Jiangsu
CHNT: +86 52380276311
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
337
Stocks News & Analysis
stocks
Undervalued by 17%, this US cybersecurity leader is a buy for 2026
Here’s a wide-moat company with strong secular tailwinds in a promising industry—and an attractive stock price, too.
stocks
Tough conditions for ASX listed wagering leader
Wagering continues to be challenged in Australia.
stocks
Chart of the Week: Inflation fears dampen sentiment on retailers
Rising inflation is the fly in the ointment.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,045.90 | 27.80 | -0.31% |
| CAC 40 | 8,325.18 | 91.26 | 1.11% |
| DAX 40 | 25,272.05 | 144.59 | 0.58% |
| Dow JONES (US) | 49,266.11 | 270.03 | 0.55% |
| FTSE 100 | 10,108.40 | 63.71 | 0.63% |
| HKSE | 26,231.79 | 82.48 | 0.32% |
| NASDAQ | 23,480.02 | 104.26 | -0.44% |
| Nikkei 225 | 51,939.89 | 822.63 | 1.61% |
| NZX 50 Index | 13,696.25 | 20.61 | -0.15% |
| S&P 500 | 6,921.46 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,717.80 | 29.10 | -0.33% |
| SSE Composite Index | 4,120.43 | 37.45 | 0.92% |